First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations

被引：0

作者：

Tomohito Kuwako

Hisao Imai

Tomomi Masuda

Yosuke Miura

Kaori Seki

Reiko Yoshino

Kyoichi Kaira

Mitsuyoshi Utsugi

Kimihiro Shimizu

Noriaki Sunaga

Yoshio Tomizawa

Shinichi Ishihara

Takao Ishizuka

Akira Mogi

Takeshi Hisada

Koichi Minato

Atsushi Takise

Ryusei Saito

Masanobu Yamada

机构：

[1] Gunma University Graduate School of Medicine,Department of Medicine and Molecular Science

[2] Gunma Prefectural Cancer Center,Division of Respiratory Medicine

[3] National Hospital Organization Nishigunma Hospital,Division of Respiratory Medicine

[4] Gunma University Graduate School of Medicine,Department of Oncology Clinical Development

[5] Kiryu Kosei General Hospital,Division of Internal Medicine

[6] Gunma University Graduate School of Medicine,Department of Thoracic Visceral Organ Surgery

[7] Isesaki Municipal Hospital,Division of Internal Medicine

[8] Public Tomioka General Hospital,Division of Internal Medicine

[9] Gunma University Graduate School of Medicine,Department of General Surgical Science

[10] Maebashi Red Cross Hospital,Division of Respiratory Medicine

来源：

Cancer Chemotherapy and Pharmacology | 2015年 / 76卷

关键词：

Non-small cell lung cancer; Advanced non-small cell lung cancer; First-line chemotherapy; mutations; Gefitinib; Elderly patients;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：761 / 769

页数：8

共 50 条

[1] First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations
Kuwako, Tomohito
Imai, Hisao
Masuda, Tomomi
Miura, Yosuke
Seki, Kaori
Yoshino, Reiko
Kaira, Kyoichi
Utsugi, Mitsuyoshi
Shimizu, Kimihiro
Sunaga, Noriaki
Tomizawa, Yoshio
Ishihara, Shinichi
Ishizuka, Takao
Mogi, Akira
Hisada, Takeshi
Minato, Koichi
Takise, Atsushi
Saito, Ryusei
Yamada, Masanobu
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 761 - 769
[2] Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations
T. Masuda
H. Imai
T. Kuwako
Y. Miura
R. Yoshino
K. Kaira
K. Shimizu
N. Sunaga
Y. Tomizawa
S. Ishihara
A. Mogi
T. Hisada
K. Minato
A. Takise
R. Saito
M. Yamada
Clinical and Translational Oncology, 2015, 17 : 702 - 709
[3] Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations
Masuda, T.
Imai, H.
Kuwako, T.
Miura, Y.
Yoshino, R.
Kaira, K.
Shimizu, K.
Sunaga, N.
Tomizawa, Y.
Ishihara, S.
Mogi, A.
Hisada, T.
Minato, K.
Takise, A.
Saito, R.
Yamada, M.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (09) : 702 - 709
[4] Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation
An, Chaolun
Zhang, Jiajun
Chu, Hongjun
Gu, Chunyan
Xiao, Feng
Zhu, Fengwei
Lu, Rujian
Shi, Hai
Zhang, Hongfei
Yi, Xin
PATHOLOGY & ONCOLOGY RESEARCH, 2016, 22 (04) : 763 - 768
[5] First-Line Gefitinib in Patients Aged 75 or Older With Advanced Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations NEJ 003 Study
Maemondo, Makoto
Minegishi, Yuji
Inoue, Akira
Kobayashi, Kunihiko
Harada, Masao
Okinaga, Shoji
Morikawa, Naoto
Oizumi, Satoshi
Tanaka, Tomoaki
Isobe, Hiroshi
Kudoh, Shoji
Hagiwara, Koichi
Nukiwa, Toshihiro
Gemma, Akihiko
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : 1417 - 1422
[6] Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer
Imai, Hisao
Wasamoto, Satoshi
Yamaguchi, Ou
Suzuki, Kensuke
Sugiyama, Tomohide
Uchino, Junji
Minemura, Hiroyuki
Osaki, Takashi
Ishii, Hisashi
Umeda, Yukihiro
Mori, Keita
Kotake, Mie
Kagamu, Hiroshi
Morozumi, Nobutoshi
Taniguchi, Hirokazu
Kasai, Takashi
Minato, Koichi
Kaira, Kyoichi
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (02) : 457 - 466
[7] Efficacy and Safety of First-Line Pembrolizumab Monotherapy in Elderly Patients (Aged ≥ 75 years) with Non-Small Cell Lung Cancer
Sugiyama, T.
Imai, H.
Wasamoto, S.
Yamaguchi, O.
Suzuki, K.
Uchino, J.
Minemura, H.
Osaki, T.
Ishii, T.
Umeda, Y.
Taniguchi, H.
Kasai, T.
Minato, K.
Kaira, K.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S453 - S453
[8] Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer
Hisao Imai
Satoshi Wasamoto
Ou Yamaguchi
Kensuke Suzuki
Tomohide Sugiyama
Junji Uchino
Hiroyuki Minemura
Takashi Osaki
Hisashi Ishii
Yukihiro Umeda
Keita Mori
Mie Kotake
Hiroshi Kagamu
Nobutoshi Morozumi
Hirokazu Taniguchi
Takashi Kasai
Koichi Minato
Kyoichi Kaira
Journal of Cancer Research and Clinical Oncology, 2020, 146 : 457 - 466
[9] First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901
Takahashi, Kosuke
Saito, Hiroshi
Hasegawa, Yoshinori
Ando, Masahiko
Yamamoto, Masashi
Kojima, Eiji
Sugino, Yasuteru
Kimura, Tomoki
Nomura, Fumio
Ogasawara, Tomohiko
Shindoh, Joe
Yoshida, Norio
Suzuki, Ryujiro
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (04) : 721 - 727
[10] FIRST-LINE GEFITINIB THERAPY FOR ELDERLY PATIENTS WITH NON-SMALL CELL LUNG CANCER HARBORING EGFR MUTATION: CENTRAL JAPAN LUNG STUDY GROUP 0901
Takahashi, Kosuke
Saito, Hiroshi
Hasegawa, Yoshinori
Ando, Masahiko
Yamamoto, Masashi
Kojima, Eiji
Sugino, Yasuteru
Kimura, Tomoki
Yokoyama, Toshihiko
Ogasawara, Tomohiko
Shindoh, Joe
Yoshida, Norio
Suzuki, Ryujiro
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S601 - S601

← 1 2 3 4 5 →